SCHEMBL652017

SCHEMBL652017

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
CNR2 P34972 2/20 0.41
CNR1 P21554 1/20 0.41
CRHR1 P34998 6/20 0.40
TSHR P16473 2/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
DHFR P00374 4/20 0.36
P2RX7 Q99572 1/20 0.35
ICMT O60725 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650191 0.92 C5AR1 (0.41) C5AR1CNR2CNR1CRHR1TSHR
SCHEMBL648196 0.92 C5AR1 (0.43) C5AR1CNR2CNR1CRHR1TSHR
SCHEMBL651879 0.92 C5AR1 (0.43) C5AR1CNR2CNR1CRHR1TSHR
SCHEMBL649714 0.89 C5AR1 (0.43) C5AR1CNR2CNR1CRHR1TSHR
SCHEMBL648114 0.89 C5AR1 (0.43) C5AR1CNR2CNR1CRHR1TSHR
SCHEMBL650673 0.89 C5AR1 (0.60) C5AR1CNR2CNR1TSHRKDM4E
SCHEMBL5136901 0.89 C5AR1 (0.46) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL650105 0.88 C5AR1 (0.46) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5135238 0.88 C5AR1 (0.45) C5AR1CNR2CRHR1TSHRKDM4E
SCHEMBL1912954 0.86 C5AR1 (0.45) C5AR1CNR2CNR1CRHR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed